We hypothesize that upregulation of BFL-1, in addition to NFκB targets BCL-XL and BCL-2, could contribute to the therapy resistance of MM PC and propose that (in)direct targeting of BFL-1 may provide a new approach for a subset of RR-MM patients. Here, BCL2L1 is linked to Miyoshi myopathy.